Summary: A competitive enzyme immunoassay was developed to determine chondroitin-6-sulphate in body fluids and cell cultures. The assay uses a monoclonal anti-chondroitin-6-sulphate antibody, immobilised to microtitre plates, and it involves a competitive binding reaction between chondroitih-6-sulphate in the samples and the biotinylated antigen.
Introduction
attached to a core protein to form proteoglycans. The macromolecule is synthesised in the Golgi apparatus, Chondroitin sulphate consists of repeated disaccharide transported to the ceil surface and secreted into the exunits containing N-acetyl-jD-galactosamine and Z)-glu-tracellular space (2) . Chondroitin sulphate is a major and curonic acid. This glycosaminoglycan is sulphated either ubiquitous component of the extracellular matrix of conon the C4 or C6 position of the amino sugar (1) and nective tissues (1) . Several methods for the determi-nation of chondroitin sulphate have been described. These techniques use enzymatic digestion, precipitation and Chromatographie methods, especially high performance liquid chromatography (3, 4) .
Methods have been reported recently, which use specific antibodies against different components of proteoglycans (e.g. keratan sulphate, dermatan sulphate) (5) (6) (7) (8) . So far, an enzyme immunoassay of chondroitin sulphate has not been described. The assay described here uses a monoclonal anti-chondroitin-6-sulphate antibody (9) and involves a competitive binding reaction between chondroitin-6-sulphate in the sample and biotinylated chondroitin-4-sulphate s labelled antigen. This enzyme immunoassay enables the determination of chondroitin-6-sulphate in serum, urine and cell culture medium.
Materials and Methods

Materials
Bovine serum albumin was obtained frorn Merck, Darmstadt. Tween 20, o-phenylenediamine, l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, monoclonal anti-chondroitin-6-sulphate antibody (CS 56), adipic acid dihydrazide and N-hydroxysuccinimidobiotin were purchased from Sigma, Deisendorf. Streptavidincoupled horse radish peroxidase 1 ) was firom Boehringer, Mannheim, and chondroitinase ABC 1 ) from Seikagaku, Tokyo. Maxisorb immunoplates were obtained from Nunc, Wiesbaden. Chondroitin-6-sulphate and chondroitin-4-sulphate were obtained from Medac, Hamburg and from Sigma, Deisendorf. All chemicals used were of analytical grade or the highest commercially available grade.
Methods
Prepara on of biotinylated antigen
Chondroitin sulphate (500 mg) was dissolved in 3 ml adipic acid dihydrazide (40 g/l, pH 4.75) and shaken for 30 min at room temperature. The solution was incubated for l hour at 4°C with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide in a ratio of l : 100 by vol. After dialysis, 2 g/l N-hydroxysuccinimidobiotin were added and the solution was incubated for 2 hours. After further dialysis the biotinylated antigen was stored at -20 °C.
Enzyme immunoassay
The wells of a plastic microtitre plate were coated overnight at 4 °C with the anti-chondroitin-6-sulphate antibody (50 μΐ/well, l : 2000 dilution of the ascitic fluid in 0.1 mol/1 phosphate-buffered saline (8.0 g/l NaCl, 0.2 g/l KC1, 0.2 g/l KH 2 PO 4 , 1.1 g/l K 2 HPO 4 , pH 7.4)) overnight at 4 °C. The coating solution was removed and the plates were washed three times with phosph te-buffered saline and blocked with bovine serum albumin (2 g/l phosphate-buffered saline, 100 μΐ/well) at room temperarure for l hour. Samples (50 μΐ/well) or chondroitin-6-sulphate Standard diluted in phosphatebuffered saline-Tween were added. After incubation for two hours at 4 °C, 50 μΐ of the biotinylated antigen were added to each well for l hour at 4 °C. The wells were washed three times with phosphate-buffered saline-Tween, then 50 μΐ streptavidin horse-radish peroxidase (60 U/l) were added and the solution was incubated for one hour at 4 °C. The wells were washed with phosphate-buffered saline and incubated with 50 μΐ of freshly prepared -phenylenediamine (60 g/l) at room temperature for 45 minutes. The enzymatic colour development was stopped by adding 50 μΐ 0.5 mol/1 sulphuric acid and the absorbance was measured at 492 nm with a Behring microtitre enzyme immunoassay reader.
Analysis of chondroitin sulphates by high performance liquid chromatography
The chondroitin-6-sulphate used s Standard and the chondroitin-4-sulphate used s biotinylated antigen were anaiysed by high performance liquid chromatography to deterrnine the composition of unsaturated chondroitin-suiphate disaccharide. The HPLC analysis of the disaccharide was carried out according to a modified method of E. Gurr et al. (4) . C^labelled chondroitin^6-sulphate in the medium of c ltured human chondrocytes was measured by the enzyme immunoassay s described above. In a parallel experiment, after the competitive binding reaction, the microtitre wells were incubated with trypsin (3 g/l) to detach the l4 C-labelled antigen/ antibody complex from the microtitre plates. This enzymatic digest ion enabled quantification of radioactivity in a scintillation well. This method will be published elsewhere (10) .
Recovery, precision and detection limit ofthe enzyme immunoassay
The accuracy ofthe enzyme immunoassay was investigated by adding a constant amount of chondroitin-6-sulphate (60 mg) to 0.1 mol/1 phosphate-buffered saline, to an albumin solution (40 g/I in phosphate-buffered saline), and to a cell culture medium (containing 100 ml/l foetal calf serum). The concentration of chondroitino^sulph te was determined before and fter addition, and the recovery was calculated.
Different concentrations of chondroitin-6^sulphate (20, 80 and 120 μg/l) were used to determine the inter-assay (n = 70) and intra^-assay (n = 15) Variation coefficients.
To determine the detection limit of the enzyme immunoassay, chondroitin-6-sulphate was added in concentrations of 0, 4, 8 and 16 μg/l to 0.1 mol/1 phosphate-buffered saline and to an albumin solution (40 g/l in phosphate-buffered saline). The low 3s-iimit (x-3s) of the chondroitin-6-sulphate-free samples was calculated after a series of 48 determinations. The lowest chondroitin-6-sulphate concentration (mean of 48 determinations), which was significantly different from this calculated value, was defined s the detection limit.
Sample preparation 1. Venous blood was obtained from healthy male (n = 90) and female (n = 90) donors aged 18-65. After clotting, followed by centrifugation for 10 minutes at 4000 min" 2. The urine collection started in the moming by rejecting the vious night urine and finished after 24 hours by including the subsequent night urine. This urine collection avoids any influence of circadian rhythm effects on the chondroitin-6-sulphate determination. Urine from 16 healthy male and 10 -healthy female volunteers were tested.
3. Human chondrocytes were precultivated s a monolayer for 24 hours in Dulbecco's modified Eagles medium supplemented with heat-inactivated foetal calf semm (50 ml/l), antibiotics and mediators. After 24 hours, fresh medium containing the mediators and [ l4 C]glucosamine hydrochloride 56 MBq/I was added. The culture media were collected and the chondroitin-6-sulphate concentration and specific incorporation rates were determined. The following mediator concentrations were used: interleukin-ΐα (lO 4 U/l), tumour necrosis factor α (100 μg/l), γ-interferon (2 · l O 5 U/l) and lipopolysaccharide (10 μg/l). The mediator concentrations were chosen accord ig to dose-response studies in which the efficacy of these concentrations was demonstrated (10) .
Statistical analysis
The signrficance of the mean value difference and the age and sex dependence of chondroitin-6-sulphate were calculated using Student's t test and linear correlation analysis, respectively.
Results
Analysis of chondroitin-6-sulphate and chondroitin-4-sulphate by high performance liquid chromatography
The chondroitin-6-sulphate used s a Standard contained 78.3% chondroitin-6-sulphate and 21.7% chondroitin-4-sulphate. The dose response curve of the enzyme immunoassay was established on the basis of the amount of chondroitin-6-sulphate in the Standard. The composition of chondroitin-4-sulphate was 89.5% chondroitin-4-sulphate, 4.5% chondroitin-6-sulphate and 6% nonsulphated chondroitin (chondroitin-0-sulphate).
Biotinylatio of antigens
The binding affi'nity of the biotinylated chondroitin-6-sulphate and biotinylated chondroitin-4-sulphate to the monoclonal antibody was investigated. The antigenicity of chondroitin-6-sulphate was considerably reduced after biotinylation ( fig. 1 ). Despite several modifications of the biotinylating reaction it was not possible to increase the antigenicity of biotinylated chondroitin-6-sulphate. However, the antigenicity of chondroitin-4-sulphate was not influenced by biotinylation, so this was used s the competitive antigen in an optimal concentration of 100 mg/l.
Dose response c rve of the enzyme immunoassay
The dose response curve of the enzyme immunoassay was obtained by using the biotinylated chondroitin·ŝ lphate s competitive antigen ( fig. 2 ). Corresponding Standard curves were obtained using 0.1 mol/I phosphate-buffered saune and albumin (40 g/l in 0.1 mol/1 phosphate-buffered salme). In addition, the Standard curve of chondroitin-6-sulphate in foetal calf serum (100 ml/l) showed a similar course. The linearity of the dose response curve was found at a concentration of 16-120 μ §/1. Matrix effects were observed only at a chondroitin-6-sulphate concentration of 80 μ^Ι. The difference between the phosphate-buffered saline Standard curve and the albumin Standard curve was 8%. However, the difference was within the Standard deviation. At all other concentrations the differences were less than 5%.
Cross-reactivity of the enzyme irnmunoassay with other glycosaminoglycans
Cross-reactivity is defined äs 50% Inhibition of binding of glycosaminoglycans to the monoclonal antibody. The 50% Inhibition point of chondroitin-6-sulphate was found at 27 g/l. The concentration of chondroitin-4-sulphate required for 50% Inhibition was 112 g/l, i.e. about 4000 times greater than that required for the equivalent Inhibition by chondroitin-6-suiphate. The cross-reaction of other glycosaminoglycans was considerably outside the linear ränge of chondroitin-6-sulphate ( fig. 3 ). The concentrations of these glycosaminoglycans causing 50% Inhibition were: dermatan sulphate l g/l, keratan sulphate > l g/l, hyaluronan > 5 g/l, arid heparin > 10 g/l.
' . N Precision, recovery and detection limit of the chondroitin-6-sulphate irnmunoassay
The inter-assay and intra-assay Variation coefficients are less than 9.0% and 6.5%, respectively ( fig. 4) . The recovery of chondroitin-6-sulphate was in the ränge of 87.5%-109.6% (tab. 1). The detection limit was 16 (tab. 2). Concentration of chondroitin-6-sulphäte iri blood serum
The normal ränge of chondroitin-6-sulphate in blood seriim was 55 -169 §/1. In the serum of healthy males the mean chondroitin-6-sulphate concentration was 101 §/1 (95% ränge: 56-169 pg/l) and in females 99 g/l (95% ränge: 61-150 g/l). No sex ör äge dependeüce was found (fig. 5) .
· J Tab. 2 Evaluation of the detection limit of the enzyme immunoassay. The absorbance of the enzyme immunoassay was measured using samples with and without small amounts of chondroitin-6-sulphate in 0. Concentration of chondroitin*6-sulphate in urine
The urine conoentration of chondroitin-6-sulphate in males was 44.5 * 21.1 mg/kg creatinine (mean ± Standard deviation) and in females 53; 5 ±21.3 mg/kg creatinine. The chondroitin-6-sulphate clearance in inen was determined äs 0.41 ±. 0.22 ml X min" 1 and in women äs 0.38 ± 0.15 ml X min" 1 . No sex dependence was observed.
Determination of chondroitin-6-sulphate synthesis rate in chondrocyte culture by modificätion of the enzyme immunoassay
The synthesis of chondroitin-6-sulphate was investigated in the medium of human chondrocytes cultivated with and without agents. The incorporation of I4 C-labelled galactosamine into chondroitin-6-sulphate was used äs a specific index of the synthesis rate. In comparison with chondrocytes incubated without agents, the chondroitin-6-sulphate synthesis decreased in the presence of the following agents: tumour necrosis factor (TNF a): 64.4%, interleukin-la (IL-la): 60.0%, bacterial lipopolysaccharide (LPS): 53.4%, and -interferon ( -INF): 21.6%(tab.3).
Discussion
Development of an enzyme immunoassay for chondroitin-6-sulphate was made difficult by the availability of only one monoclonal IgM antibody against chondroitin-6-sulphate. We therefore used a competitive method. In our assay, a biotinylated chondroitin-4-sulphate antigen competes with the antigen in the sample for the binding sites of the antibody which was immobilised on the plastic surface of the microtitre plate. Difterent procedures were tested to optimise the biotinylation of chondroitin sulphate, since it was observed that the antigenicity of the modified chondroitin-6-sulphate had been altered. The monoclonal anti-chondroitin-6-sulphate antibody recognised the biotinylated chondroitin-6-sulphate to a lesser extent than it did the native form. The decreased antigenicity of biotinylated chondroitin-6-sulphate may be due to steric effects of the sulphate position. In contrast, the antigenicity of biotinylated chondroitin-4-sulphate was unchanged. Consequently, the biotinylated chondroitin-4-sulphate was used äs a competitive aritigen at a concentration of 100 mg/1 and reproducible dose response curves were obtained for the determination of chondroitin-6-sulphate in body fluids and cell culture media. Our method avoids the use of radiolabelled ligands and, by using enzyme immunoassay plates, has proved itself to be a rapid and efficient technique.
The biochemistry of cartilage destruction in inflammatory and degenerative joint disease has been extensively studied, arid it has been found that the loss of proteoglycans of the extracellular matrix is one of the earliest events during the pathobiochemical process (11 -13) . Thus, the measurement of proteoglycans and their catabolic products in synovial fluid and serum may provide usefiil diagnostic markers for joint diseases. However, the majority of glycosaminoglycans are ubiquitous intercellular matrix components of different connective tissues. It has been suggested that keratan sulphate is a more specific analyte, since it mainly originates frorn cartilage and, to a lesser extent, from the cornea and aorta (1) . Therefore, antibodies against these glycosaminoglycans were developed and used in several immunological assays. In some studies it has been reported that patients with osteoarthritis showed a significantly higher serum concentration of keratan sulphate than healthy volunteers. However, there is still considerable controversy äs to whether the serum concentration of keratan sulphate is a specific indication of cartilage destruction (8, (14) (15) . Chondroitin-6-sulphate is a glycosaminoglycan, which may also be used äs a diagnostic factor in connective tissue diseases, including intracellular degradation of connective tissue and the metabolic activity of connective tissue cells during repair processes. However, the diagnostic relevance of this quantity must be elucidated in further investigations.
The synovial cell culture reproSents a defined mödel for obtaining Information on the metabolism of chondroitin sulphate in the synovial System and for investigätirig the influence of different agents on the metabolism of this glycosaminoglycan. In studies on the synthesis Of chondroitin sulphate the incorporation of radiolabelled galactosamine into the glycosamirioglyean is usüally determined. However, measurement of radiolabelled chondroitin sulphate isolated from cell culture medium may lead to oversimplification of the Interpretation, because changes in the measured chondroitin sulphate concentration in the medium can be influenced by partial Steps of metabolism, such äs intracellular synthesis, secf etion into the medium, re-uptake of the macromolecule and intracellular degradation. One unsatisfäctory way which has been used to overcome this problem is the simultaneous investigation of the concentration of chondroitin-6-sulphate in the extra-, peri-or intracellular pool (16) . The new enzyme immunoassay of chondroitin-6-sulphate, in combination with the assay of the antibody bound to 14 C-labelled choiidroitin-6-sülphate, riöw enables measurement of the specific incorporation of [ 14 C]galactosamine into chondroitin-6-sulphate äs a means of quantifying the synthesis rate of this glycosaminoglycan. Therefore, amplification of the enzyme immunoassay in this way represents a useful tool for obtaining rapid Information on the synthesis of chondroitin-6-sulphate in cell culture (10) .
